Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients with Cystic Fibrosis
Intermediate End Points and Health Outcomes in rhGH-Treated Patients With CF (2)
This slide summarizes the studies that met the inclusion criteria for the CER. These studies used regression analyses to test the linkages between intermediate and long-term health outcomes.
Thirty-four studies evaluated the relationship between intermediate outcomes and mortality. Sixteen studies evaluated the relationship between intermediate outcomes and HRQoL. Children, adolescents and adults were evaluated in the included studies.
Keywords: mortality | health related quality of life | HRQoL | QoL | quality of life | cystic fibrosis | CF | rhGH | recombinant human growth hormone | human growth hormone | HGH
- Phung OJ, Coleman CI, Baker EL, et al. Effectiveness of Recombinant Human Growth Hormone (rhGH) in the Treatment of Patients With Cystic Fibrosis. AHRQ Comparative Effectiveness Review No. 23 (Prepared by University of Connecticut-Hartford Hospital Evidence-based Practice Center under Contract No. 290-2007-10067-I). Rockville, MD: Agency for Healthcare Research and Quality; October 2010. AHRQ Publication No. 11-EHC003-EF.
Your slide tray is being processed.